MingMed
因明生物
MingMed (因明生物) is a Guangzhou-based biotech company founded in October 2019 that develops first-in-class drugs with global competitiveness . The company is led by co-founder and CEO Yan Zhang , and its pipeline spans ophthalmology drugs, novel medical aesthetic drugs, small-molecule immunology drugs, and cell therapy — with over ten candidates in development, most positioned as breakthrough first-in-class innovations .
Its most advanced disclosed program is a first-in-class ophthalmology drug for dry age-related macular degeneration (dry AMD), which entered Phase I clinical trials in the U.S. in May 2021 after receiving IND approval . The company also made progress in 2021 on a novel recombinant protein aesthetic drug and small-molecule immunology candidates .
MingMed's subsidiary Yuyan Pharmaceutical (誉颜制药) has developed YY001, a recombinant botulinum toxin type A for moderate-to-severe glabellar lines that completed Phase III trials and had its marketing application accepted by China's NMPA as of late December 2024 — positioning it as the first recombinant botulinum toxin globally to enter regulatory review .
The company raised nearly $60 million in a Series A led by Gaorong Ventures in March 2021, followed by a roughly $50 million Series A+ in September 2021 in which Gaorong continued to invest, bringing total 2021 fundraising to approximately $110 million .
AI-generated — may contain errors, please verify.
Coverage
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Rongbao | Power Semiconductor, Robotics Firms "Steer" Tech Upgrades, AI Applications Make Major Debuts
The Meaning of "Exploration"
Rongbao | Generative AI Powers Industries, Snack Chains Hit 10,000 Stores, Chip Tape-Out Success, Healthcare Goes Global
Innovation lights the path to growth.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
Robots, AI, and Simulation Technologies Accelerate Industrial Adoption | Rongbao · June
Technology drives industrial transformation.
Chips, Energy Storage, and LiDAR Accelerate Commercialization; Robotics and SaaS Expand Globally | Rongbao · May
Sailing through the waves, striving upstream.
Multiple cutting-edge technologies lead globally — 3D interaction, LiDAR, chips, and medical innovation continue apace | Rongbao · March
Keep learning and evolving through the long cycle of sustained innovation.
Rongbao · November | New milestones for drug R&D, chips, and autonomous driving; UJU Media lists on Hong Kong Stock Exchange Main Board
New funding, new products, new applications.
Gaorong Bulletin · September | Gaorong Ventures Ranks Top 3 in 2021 VC Fund Returns, Milestones for Cross-Border Services, New Drug R&D, and New Brands
Consumer investment is returning to natural consumer demand, and medical technology innovation is emerging.
MingMed Completes Nearly $50 Million Series A+ Round to Accelerate Clinical Trials for Key Pipeline Candidates
Accelerating the development of globally leading first-in-class drugs.
Rongbao · May | Pinduoduo Enters the Era of 800 Million Users, Waterdrop Inc. Debuts on the NYSE
Meeting the needs of China's vast user base for a better life.
Rongbao · March | Autonomous Driving and Chip R&D Accelerate, Enterprise Service Companies Secure New Funding Amid Digitalization Wave
Nuro brings in new investors for its Series C round, Innoviz launches an automotive perception platform, and emerging consumer brands tap into Ocean Engine.
Inventage Biotech Closes Nearly $60 Million Series A to Develop Globally Leading First-in-Class Drugs
First in China, Best in the World
